Hemostatic Disorders: Clinical Trials

4,664 trials for Hemostatic Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2206 completed, 639 recruiting, 586 terminated, 470 unknown. 1862 Phase 2, 1387 Phase 1, 473 Not applicable, 459 Phase 3, 98 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21862Completed 899, Terminated 292, Recruiting 195, Active not recruiting 164, Unknown 155, Withdrawn 97, Not yet recruiting 51, Suspended 6, Enrolling by invitation 3
Phase 11387Completed 655, Terminated 244, Recruiting 171, Unknown 122, Active not recruiting 90, Withdrawn 53, Not yet recruiting 45, Suspended 7
Not applicable473Completed 203, Recruiting 91, Unknown 59, Terminated 53, Not yet recruiting 31, Active not recruiting 16, Withdrawn 14, Enrolling by invitation 3, Suspended 3
Phase 3459Completed 239, Recruiting 57, Active not recruiting 52, Unknown 47, Terminated 38, Not yet recruiting 16, Withdrawn 8, Suspended 2
Phase 498Completed 44, Unknown 15, Recruiting 14, Terminated 8, Not yet recruiting 7, Active not recruiting 5, Withdrawn 5
Early Phase 196Recruiting 29, Unknown 24, Not yet recruiting 14, Completed 11, Terminated 8, Active not recruiting 5, Withdrawn 3, Suspended 2

Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Ginger on Heavy Menstrual Bleeding in Women With Coagulation Disorders
Ginger, Placebo - Women With Coagulation Disorders
Early Phase 1Not yet recruitingUniversity of Valladolid742028-02-012026-05-19
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors
Not applicableNot yet recruitingUniversity of Vermont Medical Center332028-02-012026-08-25
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 2Not yet recruitingExcyte Biopharma Ltd642027-12-012026-11-06
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma
Individual Exercise, Group Exercise - Multiple Myeloma
Not applicableSuspendedMedical University of Vienna452027-09-012026-10-09
Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy
• Sivelestat intravenous infusion, NaCl intravenous infusion - Septic Shock, Coagulopathy
Phase 2Not yet recruitingUniversity Hospital, Strasbourg, France1202027-08-012026-08-20
Engineered Dendritic Cell Vaccines for Multiple Myeloma
DC vaccines - Multiple Myeloma or Plasmacytoma
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute102027-06-302026-11-02
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma
Phase 1WithdrawnFred Hutchinson Cancer Center2027-06-012026-09-11
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Phase 2RecruitingNational Cancer Institute (NCI)802027-05-222026-11-04
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)1622027-04-122026-10-16
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy
ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM)
Phase 2Not yet recruitingZealand University Hospital1502027-03-012026-09-25
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM)
Phase 2Not yet recruitingUniversity of Arkansas502027-03-012026-09-02
An Exercise and Lifestyle Programme for Adults With Vascular Ehlers-Danlos Syndrome: A Feasibility Study
Co-designed exercise-based lifestyle intervention - Vascular Ehlers Danlos Syndrome
Not applicableNot yet recruitingSheffield Hallam University402027-03-012026-07-13
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma
Phase 4Not yet recruitingAnne Louise Tølbøll Sørensen4002027-03-012026-03-16
Topical TOR-582 Treatment of Epistaxis in HHT
Topical sirolimus ointment - Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Phase 1Not yet recruitingColumbia University272027-03-012026-11-06
Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)
Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma
Phase 1Not yet recruitingUniversity of Chicago322027-02-232026-10-22
Teclistamab In Waldenstrom's Macroglobulinemia
Teclistamab - Waldenstrom's Macroglobulinemia
Phase 2Not yet recruitingMassachusetts General Hospital242027-02-192026-09-01
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Anitocabtagene Autoleucel, Isatuximab, Bortezomib - Newly Diagnosed Multiple Myeloma
Phase 3Not yet recruitingKite, A Gilead Company7502027-02-012026-11-16
Regenerative Medicine for Joint Hypermobility and Instability
Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS)
Phase 1 / Phase 2Not yet recruitingManhattan Pain Medicine, PLLC1002027-01-152026-10-06
Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization
rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization
Phase 2 / Phase 3Not yet recruitingThe Affiliated People's Hospital of Ningbo University702027-01-012026-09-30
Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells
Isatuximab, VRD - Multiple Myeloma
Phase 2 / Phase 3Not yet recruitingThe Affiliated People's Hospital of Ningbo University152027-01-012026-10-02

Showing 20 of 4664. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (3675)  ·  Lymphoma, Non-Hodgkin (609)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (593)  ·  Lymphoma (579)  ·  Neoplasms, Plasma Cell (526)  ·  Waldenstrom Macroglobulinemia (521)  ·  Lymphoma, Follicular (486)  ·  Lymphoma, B-Cell, Marginal Zone (469)  ·  Lymphoma, Mantle-Cell (465)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (456)  ·  Hodgkin Disease (452)  ·  Recurrence (431)  ·  Lymphoma, Large B-Cell, Diffuse (426)  ·  Leukemia (367)  ·  Leukemia, Myeloid, Acute (366)

Broader conditions

Hemic and Lymphatic Diseases (4664)  ·  Cardiovascular Diseases (4652)  ·  Vascular Diseases (4652)  ·  Hemorrhagic Disorders (4645)  ·  Hematologic Diseases (4584)  ·  Immune System Diseases (4084)  ·  Neoplasms by Histologic Type (4052)  ·  Immunoproliferative Disorders (4032)  ·  Blood Protein Disorders (4025)  ·  Paraproteinemias (4002)  ·  Lymphoproliferative Disorders (3989)  ·  Neoplasms (3853)  ·  Neoplasms, Plasma Cell (3510)  ·  Pathological Conditions, Signs and Symptoms (1344)

Interventions

Dexamethasone (855)  ·  Bortezomib (486)  ·  Lenalidomide (462)  ·  Cyclophosphamide (378)  ·  Melphalan (262)  ·  Calcium Dobesilate (249)  ·  daratumumab (237)  ·  pomalidomide (218)  ·  carfilzomib (187)  ·  fludarabine phosphate (148)  ·  Peripheral Blood Stem Cell Transplantation (134)  ·  Thalidomide (130)  ·  Rituximab (129)  ·  fludarabine (126)  ·  Filgrastim (125)

Sponsors

National Cancer Institute (NCI) (180)  ·  Mayo Clinic (100)  ·  Celgene (93)  ·  Fred Hutchinson Cancer Center (84)  ·  Memorial Sloan Kettering Cancer Center (84)  ·  M.D. Anderson Cancer Center (73)  ·  Janssen Research & Development, LLC (67)  ·  University of Arkansas (57)  ·  Dana-Farber Cancer Institute (53)  ·  Institute of Hematology & Blood Diseases Hospital, China (46)  ·  Amgen (44)  ·  GlaxoSmithKline (42)  ·  Washington University School of Medicine (40)  ·  City of Hope Medical Center (38)  ·  Massachusetts General Hospital (38)

Countries

United States (2606)  ·  France (505)  ·  China (485)  ·  Spain (349)  ·  Germany (343)  ·  Italy (334)  ·  Canada (313)  ·  United Kingdom (281)  ·  Australia (230)  ·  South Korea (181)  ·  Greece (175)  ·  Japan (169)  ·  Belgium (166)  ·  Netherlands (157)  ·  Israel (148)

Top investigators

Brenda Sandmaier (11)  ·  Robert Knight, MD (11)

Results publications

PMID 32499241, PMID 33357481, PMID 31221778, PMID 37022569, PMID 22689675, PMID 33218965, PMID 34398557, PMID 35285981, PMID 36853224, PMID 37192741, PMID 40501401, PMID 28803351, PMID 34289038, PMID 35244208, PMID 35549810, PMID 35985959, PMID 36100310, PMID 40000533, PMID 40826257, PMID 42287565, PMID 18000608, PMID 20661232, PMID 22674807, PMID 23897961, PMID 24586400, PMID 25261096, PMID 25628469, PMID 29567784, PMID 34182226, PMID 34515338, PMID 35876974, PMID 36762851, PMID 37272512, PMID 37934000, PMID 38023148, PMID 38402374, PMID 39229471, PMID 40156952, PMID 40396505, PMID 40471585, PMID 40674744, PMID 41313549, PMID 41627370, PMID 18032762, PMID 18032763, PMID 18799726, PMID 19179301, PMID 19238148, PMID 19901114, PMID 20825986

NIH funding

2023 (73), P30CA015083 (50), U10CA180820 (43), 2017 (32), P30CA015704 (32), 2019 (29), 2018 (23), 2025 (22), P30CA033572 (22), 2014 (21), U10CA032102 (21), U24CA196172 (21), P30CA006973 (20), 2016 (19), P30CA043703 (19)